GLP-1 Agonists for Cardiovascular Research: What the SELECT and LEADER Trials Tell Us

When the LEADER trial published in 2016, it changed the trajectory of GLP-1 receptor agonist research in a way that no preclinical study could have predicted. Liraglutide — previously understood primarily as a glucose-lowering agent — reduced the risk of major adverse cardiovascular events (MACE) by 13% in patients with type 2 diabetes and established cardiovascular disease. The finding was not expected by most of the field. It launched a decade of mechanistic investigation into how GLP-1R signaling interacts with the cardiovascular system, and it established a research paradigm — cardiovascular outcome trials (CVOTs) — that has since generated some of the most consequential clinical data in modern metabolic research.

For researchers working with GLP-1 axis peptides, understanding what the major CVOTs demonstrated — and, crucially, what they did not demonstrate — is essential for designing preclinical cardiovascular models with appropriate endpoints, controls, and mechanistic hypotheses. This guide covers the four key CVOTs (LEADER, SUSTAIN-6, SELECT, SURPASS-CVOT), the proposed cardiovascular mechanisms, and how to translate these findings into rigorous preclinical cardiac and vascular research protocols.

LEADER: The Trial That Started the CV Conversation

The LEADER trial (Marso et al., NEJM 2016) enrolled 9,340 adults with type 2 diabetes and high cardiovascular risk. Participants were randomized to liraglutide 1.8 mg SC daily or placebo, on top of standard care, for a median of 3.8 years. The primary composite endpoint was the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke (3-point MACE).

The results: MACE occurred in 13.0% of the liraglutide group versus 14.9% of the placebo group — a hazard ratio of 0.87 (95% CI 0.78–0.97, p<0.001 for non-inferiority, p=0.01 for superiority). Cardiovascular death drove the reduction: 4.7% vs 6.0% (HR 0.78). Rates of nonfatal MI and stroke showed trends toward reduction but were not individually significant. All-cause mortality was also reduced (HR 0.85). Notably, HbA1c reduction was only ~0.4% greater in the liraglutide arm — a modest glycemic effect relative to the magnitude of the CV benefit, suggesting the cardioprotection was not entirely glucose-mediated.

SUSTAIN-6: Semaglutide Confirms the Class Effect

SUSTAIN-6 (Marso et al., NEJM 2016) enrolled 3,297 patients with type 2 diabetes and high CV risk. Semaglutide 0.5 mg or 1.0 mg weekly SC was compared to placebo over 104 weeks. The primary endpoint was the same 3-point MACE composite.

MACE occurred in 6.6% of semaglutide-treated patients versus 8.9% of placebo (HR 0.74, 95% CI 0.58–0.95, p<0.001 for non-inferiority, p=0.02 for superiority). This 26% relative risk reduction was numerically larger than LEADER's 13%, though the shorter duration and smaller population preclude direct comparison. The result established the CV benefit as a class effect of GLP-1R agonists rather than an idiosyncratic liraglutide property. Nonfatal stroke showed a more pronounced trend (HR 0.61) than MI in SUSTAIN-6, unlike LEADER, generating mechanistic discussion about cerebrovascular vs coronary mechanisms.

SELECT: Cardioprotection Without Diabetes

SELECT (Lincoff et al., NEJM 2023) was the pivotal trial that dramatically changed how researchers interpret the cardiovascular mechanism of GLP-1R agonism. Unlike LEADER and SUSTAIN-6, SELECT enrolled 17,604 adults with established cardiovascular disease, BMI ≥27, but WITHOUT type 2 diabetes. The question SELECT asked was fundamental: is the cardioprotection from GLP-1R agonists metabolic (glucose/HbA1c-dependent) or something else?

At 33.5 months median follow-up, semaglutide 2.4 mg weekly reduced 3-point MACE by 20% (HR 0.80, 95% CI 0.72–0.90, p<0.001). This occurred in patients who were, by definition, non-diabetic. The finding was profound: GLP-1R-mediated CV protection does not require underlying glucose dysregulation. The glycemic reduction in SELECT was minimal (HbA1c decreased by only ~0.2%), yet the MACE benefit was larger than in LEADER. SELECT decoupled cardiovascular protection from glucose metabolism, forcing researchers to look upstream — toward direct vascular, inflammatory, and cardiac mechanisms.

SURPASS-CVOT: Extending CV Data to Dual Agonism

SURPASS-CVOT (Cardiovascular safety of tirzepatide in type 2 diabetes) was designed as a non-inferiority trial against dulaglutide, a GLP-1R monoagonist. The trial enrolled 13,000+ patients with T2D and established CV disease or multiple risk factors. The key question: does adding GIPR agonism to GLP-1R agonism alter cardiovascular risk relative to a GLP-1R monoagonist comparator?

Published results demonstrated tirzepatide met non-inferiority against dulaglutide on the 3-point MACE composite (HR ~0.85, upper bound <1.05), with a trend toward superiority that was not statistically significant in the primary analysis. The weight loss differential between arms — tirzepatide produced ~5% greater weight loss than dulaglutide — adds a confounding variable when interpreting whether any additional GIPR-mediated CV effects are present. SURPASS-CVOT suggests the GIP pathway does not harm the cardiovascular system and may offer additional benefit, but the definitive mechanistic dissection awaits head-to-head GCVOT designs with placebo control.

Proposed Cardiovascular Mechanisms: What the CVOTs Didn't Prove

The CVOT data establishes that GLP-1R agonists reduce MACE. It does not establish why. Several mechanisms have been proposed based on preclinical and small clinical studies, but causation remains an open research question:

• Direct cardiac GLP-1R signaling: GLP-1Rs are expressed on cardiomyocytes and cardiac endothelial cells. Preclinical models (rat I/R injury, H9c2 cardiomyocyte cultures) show GLP-1R activation reduces infarct size via cAMP/PKA/CREB anti-apoptotic signaling (Bose et al., Circulation 2005). Whether this contributes to the clinical MACE reduction is not established.
• Anti-inflammatory effects on VSMC: GLP-1R agonists reduce NF-κB activity in vascular smooth muscle cells, attenuate macrophage foam cell formation, and reduce circulating CRP and IL-6 in clinical studies (Marso 2016 LEADER subanalyses). The SELECT trial's weight-independent benefit is particularly supportive of an inflammation-mediated mechanism.
• Plaque stabilization: Several imaging substudies (SUSTAIN-6 coronary CTA substudy) showed reductions in coronary plaque volume with semaglutide, suggesting GLP-1R agonists may reduce atherosclerotic plaque burden or alter composition (toward stable, fibrous cap-rich phenotype).
• Blood pressure and heart rate effects: GLP-1R agonists consistently reduce systolic blood pressure by 2–4 mmHg and increase resting heart rate by 2–4 bpm. The antihypertensive effect is cardioprotective; the chronotropic effect has generated discussion about long-term implications.
• Renal protection: LEADER and SELECT both showed reductions in albuminuria and estimated GFR decline. Cardiorenal syndrome — where renal impairment worsens cardiac outcomes — may be a contributing mechanism to the CV benefit.
• Natriuresis and fluid homeostasis: GLP-1Rs are expressed in the kidney proximal tubule and reduce sodium reabsorption. The resulting natriuresis may reduce preload, contributing to cardiac benefit particularly in heart failure models.

Preclinical Cardiac Rodent Models

Researchers seeking to mechanistically dissect the GLP-1R cardiovascular effects have several well-validated preclinical model options:

• Transverse aortic constriction (TAC): Pressure-overload heart failure model. GLP-1R agonists have shown attenuation of cardiac hypertrophy and preservation of ejection fraction in TAC models at doses of 0.1–1.0 mg/kg SC/day. Semaglutide and liraglutide data available.
• Ischemia/reperfusion (I/R) injury: Left anterior descending coronary artery ligation + reperfusion. GLP-1R agonists reduce infarct size (assessed by TTC staining) and preserve LVEF (echocardiography) when administered before reperfusion or during reperfusion. Exendin-4 at 0.1–1.0 nmol/kg IV pre-reperfusion is the most replicated protocol.
• HFD cardiac hypertrophy: C57BL/6J mice on 60% kcal HFD develop concentric cardiac hypertrophy (echocardiographic LV wall thickening, LVMI increase, diastolic dysfunction). GLP-1R agonists normalize LV geometry and LVMI over 8–16 weeks at 0.1–0.3 mg/kg SC 1×/week.
• STZ-induced diabetic cardiomyopathy: Streptozotocin destroys pancreatic beta cells, producing hyperglycemia and secondary cardiomyopathy. GLP-1R agonists show cardiac benefit in STZ models, but the glycemic confound requires careful design (pair with insulin replacement groups to dissect glycemic vs direct cardiac mechanism).
• GLP-1R knockout validation model: GLP-1R-KO mice (B6;129S5-Glp1rtm1Lex, Jackson Labs #004700) are the critical tool for establishing on-target cardiac effects. Any cardiac effect abolished in GLP-1R-KO mice is receptor-mediated; persistent effects suggest off-target or downstream mechanisms.

Key Cardiovascular Endpoints for Preclinical Research

Selecting appropriate endpoints is critical for translational cardiovascular research with GLP-1R agonists:

• Echocardiography: LVEF (systolic function), E/A ratio and E/e' (diastolic function), LV wall thickness and internal diameter, fractional shortening. Recommended timing: baseline, mid-study, endpoint. Requires mouse-optimized probe (30–40 MHz).
• Infarct size quantification: TTC (triphenyltetrazolium chloride) staining at 24h post-I/R. Reports infarct volume as % of area at risk. Requires Evans Blue perfusion for area-at-risk demarcation.
• Cardiac fibrosis: Masson's trichrome staining (collagen % of cardiac section), picrosirius red under polarized light for collagen type I/III ratio.
• Cardiac hypertrophy markers: Heart weight/body weight ratio, heart weight/tibia length ratio (corrects for obesity-related body weight inflation). HW/TL is preferred for metabolic studies. RT-qPCR for ANP (Nppa), BNP (Nppb), and β-MHC (Myh7) fetal gene program.
• Inflammatory markers: Cardiac macrophage infiltration (F4/80 IHC), NF-κB nuclear translocation (p65 IHC), plasma IL-6/TNF-α (Luminex or ELISA).
• Vascular function: Aortic ring relaxation assay (acetylcholine-induced endothelium-dependent relaxation as % of phenylephrine precontraction) for endothelial function. eNOS phosphorylation (pSer1177-eNOS western) as molecular endpoint.

Research Design Considerations

Six critical study design considerations for GLP-1R cardiovascular research:

• GLP-1R-KO controls are essential, not optional. Without a receptor knockout or pharmacological antagonist (exendin(9-39) at 100 µg/kg IP, or GLP-1R antagonist AC-262536) arm, you cannot distinguish on-target GLP-1R cardiac effects from weight loss, glucose-lowering, or blood pressure effects. This is the single most common design flaw in GLP-1R cardiac papers.
• Pair-fed controls dissect metabolic confounding. If your GLP-1R agonist-treated animals eat less (they will), weight loss and its downstream cardiac effects confound cardiac endpoint interpretation. Pair-fed control animals caloric-restricted to match treated group intake allow isolation of direct receptor-mediated effects from caloric deficit effects.
• Endpoint timing must account for steady state. Semaglutide and CJC-1295/DAC have long half-lives — 5–7 days in rodents for semaglutide. Cardiac endpoints assessed before steady state (typically 4–5 weeks for weekly dosing) will underestimate effect magnitude. Echocardiography at week 8–12 is the minimal recommendation for chronic cardiac remodeling studies.
• Consider the chronotropic effect as a confound. GLP-1R agonists increase heart rate by 2–5 bpm in mice and rats via sympathetic activation. In cardiac I/R models, elevated heart rate increases myocardial oxygen demand and can worsen ischemic injury independently of the cardioprotective signaling. Rate-control with atenolol (pre-specified) or heart rate covariate analysis may be needed.
• Sex differences in GLP-1R cardiac expression. Female rodents show higher GLP-1R expression in cardiomyocytes in some models, with correspondingly larger cardioprotective effects. Design studies with adequate sex stratification; do not pool sexes without prior justification.
• Mechanistic dissection: use pathway inhibitors in vitro before committing to in vivo. Cell-based systems (H9c2 cardiomyocytes, neonatal rat ventricular myocytes, human iPSC-derived cardiomyocytes) allow pharmacological dissection of which downstream pathway (PKA, Epac1/2, PI3K/Akt, AMPK) is responsible for GLP-1R cardioprotection before animal studies are designed around that mechanism.

Translating CVOT Findings to Preclinical Protocol Design

The SELECT trial's weight-independent cardiovascular benefit is the most tractable finding for preclinical mechanistic research. It narrows the hypothesis space: the mechanism is not purely mediated through adiposity reduction, glycemic control, or insulin sensitization. Researchers investigating SELECT's mechanistic underpinning should focus on: direct vascular inflammation endpoints (macrophage foam cell formation, VSMC NF-κB, plaque composition in ApoE-/- atherosclerosis models), direct cardiac GLP-1R signaling (using the I/R model with GLP-1R-KO and exendin(9-39) controls), and renal GLP-1R effects (tubular sodium handling, cardiorenal crosstalk in CKD + heart failure combination models).

The SURPASS-CVOT non-inferiority result, combined with tirzepatide's greater weight loss and metabolic effects, makes GLP-1R/GIPR dual agonism a priority research area. Adding a tirzepatide arm to semaglutide-only cardiac studies — with appropriate receptor-selective antagonist controls — can dissect whether GIPR agonism provides additive cardiovascular benefit, particularly in non-obese models where the weight-loss confounder is removed.

Reconstitution and Storage for Cardiac Research Protocols

For acute cardiac I/R protocols: dissolve lyophilized GLP-1R agonist (semaglutide, liraglutide, or exendin-4) in sterile saline at pH 7.0–7.4 for IV administration. BAC water is acceptable for SC dosing in chronic models but is contraindicated for IV administration due to benzyl alcohol cardiac toxicity at the volumes used in rodent IV protocols. Prepare fresh solutions daily for IV acute studies. For chronic SC models: 1 mg/mL working solution in BAC water, stored at 4°C for up to 4 weeks (semaglutide) or 2 weeks (liraglutide, exendin-4). All solutions: amber vials, minimize UV exposure.

Store lyophilized semaglutide at −20°C; working solutions at 4°C. Tirzepatide lyophilized: −20°C preferred; reconstituted at 5 mg/mL in BAC water, 4°C up to 4 weeks. Low-bind (polypropylene) tubes required for dilute solutions below 0.5 mg/mL to prevent adsorption losses that would compromise dose accuracy in cardiac dose-response studies.

The cardiovascular outcome data from LEADER, SUSTAIN-6, SELECT, and SURPASS-CVOT represents some of the most reproducible and impactful clinical evidence in modern metabolic medicine. For preclinical researchers, it provides a rich hypothesis space — weight-independent cardioprotection, direct vascular anti-inflammatory effects, cardiac GLP-1R signaling — that is far from mechanistically resolved. The next decade of GLP-1R cardiovascular research will almost certainly be defined by experiments designed to answer why SELECT worked, not just that it did.